Amanote Research
Register
Sign In
Alk Expression Plays Different Roles in Anaplastic Large-Cell Lymphomas and Outcome of Crizotinib Use in Relapsed/Refractory Alk+ Patients in a Chinese Population
Hematological Oncology
- United Kingdom
doi 10.1002/hon.2439_155
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Cancer Research
Oncology
Hematology
Date
June 1, 2017
Authors
W. Li
L. Huang
F. Zhang
J. Zeng
H. Guo
S. Liu
X. Wei
Z. Liang
F. Chen
X. Jiang
Y. Chen
Y. Liu
Publisher
Wiley
Related search
Three Years Sustained Complete Remission Achieved in a Primary Refractory ALK-positive Anaplastic T Large Cell Lymphoma Treated With Crizotinib
Rare Tumors
Oncology
Histology
ALK-negative Anaplastic Large Cell Lymphoma
Overcoming Resistance in Relapsed Anaplastic Large-Cell Lymphoma, ALK-Positive (Literature Review and Clinical Experience)
Klinicheskaya Onkogematologiya/Clinical Oncohematology
Oncology
Hematology
Prognostic Significance of NPM-ALK Fusion Transcript Overexpression in ALK-positive Anaplastic Large-Cell Lymphoma
Modern Pathology
Forensic Medicine
Pathology
CDC37 as a Novel Target for the Treatment of NPM1-ALK Expressing Anaplastic Large Cell Lymphomas
Blood Cancer Journal
Oncology
Hematology
Reactive Oxygen Species and Lipoxygenases Regulate the Oncogenicity of NPM-ALK-positive Anaplastic Large Cell Lymphomas
Oncogene
Cancer Research
Genetics
Molecular Biology
Leukemic Phase of ALK-positive Anaplastic Large Cell Lymphoma
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Secondary CNS Involvement of ALK-negative Anaplastic Large Cell Lymphoma
American Journal of Hematology
Hematology
Dusp22 and Tp63 Rearrangements Predict Outcome of Alk-Negative Anaplastic Large Cell Lymphoma: A Danish Cohort Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
